Variation of hormonal receptor, pS2, c-erbB-2 and GSTpi contents in breast carcinomas under tamoxifen: a study of 74 cases.

por Soubeyran, I., Quénel, N., Mauriac, L., Durand, M., Bonichon, F., Coindre J-M
Publicado 1996

pS2 protein: a marker improving prediction of response to neoadjuvant tamoxifen in post-menopausal breast cancer patients.

por Soubeyran, I., Quénel, N., Coindre, J. M., Bonichon, F., Durand, M., Wafflart, J., Mauriac, L.
Publicado 1996

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

por MacGrogan, G., Mauriac, L., Durand, M., Bonichon, F., Trojani, M., de Mascarel, I., Coindre, J. M.
Publicado 1996

DNA topoisomerase IIα expression and the response toprimary chemotherapy in breast cancer

por MacGrogan, G, Rudolph, P, Mascarel, I de, Mauriac, L, Durand, M, Avril, A, Dilhuydy, J M, Robert, J, Mathoulin-Pélissier, S, Picot, V, Floquet, A, Sierankowski, G, Coindre, J M
Publicado 2003

High rate of extra-haematological toxicity compromises dose-dense sequential adjuvant chemotherapy for breast cancer

por Brain, E, Levy, C, Serin, D, Roché, H, Spielmann, M, Delva, R, Veyret, C, Mauriac, L, Rios, M, Martin, A L, Jimenez, M, Asselain, B, Gauthier, M, Bonnetain, F, Fumoleau, P
Publicado 2011

Summary version of the standards, options and recommendations for nonmetastatic breast cancer (updated January 2001)

por Mauriac, L, Luporsi, E, Cutuli, B, Fourquet, A, Garbay, J R, Giard, S, Spyratos, F, Sigal-Zafrani, B, Dilhuydy, J M, Acharian, V, Balu-Maestro, C, Blanc-Vincent, M P, Cohen-Solal, C, De Lafontan, B, Dilhuydy, M H, Duquesne, B, Gilles, R, Lesur, A, Shen, N, Cany, L, Dagousset, I, Gaspard, M H, Hoarau, H, Hubert, A, Monira, M H, Perrié, N, Romieu, G
Publicado 2003